Leukemia Clinical Trials

Showing 6461-6480 of 10,987 trials

UNKNOWN

Prognostic Value of CD318 in AML at Assiut University Hospital.

NCT04708444

We will focus on the prognostic value of CD318 in acute myeloid leukemia patients at Assiut University Hospital

Acute Myeloid Leukemia

Shimaa Arafa Ibrahim100 participantsStarted Mar 2021

TERMINATEDPhase 1

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

NCT03601819

This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.

Lymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralChronic Lymphocytic Leukemia+4 more

University of Michigan Rogel Cancer Center4 participantsStarted May 2019

Ann Arbor, Michigan, United States

COMPLETED

Prevalence of Deep Sedation in Terminal Palliative Phase

NCT04333719

This nation-wide, multicentric, prospective and cross-sectional study aims to estimate the prevalence of deep sedations (i.e. with a -4 or -5 score at the Richmond scale at the induction time) for patients in terminal phase and receiving cares from a specialized palliative care facility (palliative care units, dedicated beds in acute units, mobile teams for inpatient or outpatients or home-based structures) in France.

Palliative CareDeep Sedations

University Hospital, Bordeaux183 participantsStarted Sep 2020

Bordeaux, Aquitaine, France

UNKNOWN

Impact of Low Muscle Mass in HNC Treated With Immunotherapy

NCT04721184

The purpose of the study is to evaluate the baseline muscle mass as a predictive biomarker of treatment response in patients with recurrence or metastatic squamous cell carcinoma of the head and the neck (SCCHN) treated with immune checkpoint inhibitors (ICI)

Head and Neck Small Cell CarcinomaSarcopenia

Institut Català d'Oncologia120 participantsStarted Jan 2021

L'Hospitalet de Llobregat, Barcelona, Spain

Prognostic Value of CD318 in AML at Assiut University Hospital.

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

Prevalence of Deep Sedation in Terminal Palliative Phase

Impact of Low Muscle Mass in HNC Treated With Immunotherapy

Related Searches

Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Kansas City Community Environmental Remediation And Training (KC CERT)

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy

IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Effect of NPO Time and Type of Food Intake on Preoperative Residual Gastric Content and pH

Pediatric In-Hospital Cardiac Arrest International Registry (PACHIN)

Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive

Psychological Factors That Influence Severity of Allergic Rhinitis

Development of a Multivariable Prognostic PREdiction Model for 1-year Risk of FALLing in Community-dwelling Older Adults in a Non-clinical Setting

Postoperative Pain After Using NiTi Instruments

Phenotyping of Small Bowel Adenocarcinoma

The Efficacy and Security of the Small Stitch Technique in Emergency Surgery